Figure 2.

Dolutegravir (DTG) is associated with an acceleration in body mass index (BMI) increase. Predictions were constructed using the following covariate values: male, 14 years old at DTG transition, previously on nevirapine-based antiretroviral therapy, and transitioned to tenofovir disoproxil fumarate/lamivudine/DTG. Predicted BMI and 95% predictive intervals (PIs) were constructed using estimates and the associated standard error of prediction from the fully adjusted model fitted in those who were thin, normal weight, or obese/overweight prior to DTG transition.